Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 67% of Pharmacies Have Demanded Premium for Generics Dispensing System
October 20, 2008
- Eli Lilly to Acquire ImClone for US$6.5 Billion
October 20, 2008
- Final Draft of Peptic Ulcer Guidelines Approved
October 20, 2008
- Novartis Enhances Sales/Marketing by Therapeutic Category
October 20, 2008
- Routine Use of PCV7 Is Cost-Effective: Wyeth
October 20, 2008
- BUSINESS NEWS IN BRIEF
October 20, 2008
- Japan's First ACS Patient Registry Study PACIFIC Underway
October 20, 2008
- Thalidomide to Be Approved for Multiple Myeloma
October 20, 2008
- Astellas Completes New Buildings in Its Tsukuba Research Center
October 20, 2008
- Industry Should Stress Contribution to Healthcare: Mr Kinoshita
October 20, 2008
- Kissei's Silodosin Approved in US
October 20, 2008
- To Promote Use of Generics or Cut Prices of Original Drugs?
October 20, 2008
- Otsuka Extends Joint Research Program with Galenea for 1 Year
October 20, 2008
- NEW PRODUCTS
October 20, 2008
- R&D NEWS IN BRIEF
October 20, 2008
- Teijin Acquires another Home Therapy Equipment Provider in US
October 20, 2008
- Mediceo Paltac, Alfresa to Merge to Create a \4 Trillion Wholesaler
October 20, 2008
- FALCO Signs CYP2D6*4 Gene Patent Licensing Agreement with LGC
October 20, 2008
- REGULATORY NEWS IN BRIEF
October 13, 2008
- NEW PRODUCTS
October 13, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…